A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction
| Registry | NCT00529932, acronym SELECT-AMI |
|---|---|
| Status | Terminated - Insufficient recruitment |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: quadruple, treatment |
| Enrollment | 19 (Actual) |
| Sponsor | Jozef Bartunek (Other); collaborators: King's College London |
| Conditions | Acute Myocardial Infarction |
| Interventions | CD133+ infusion, placebo infusion (Other) |
| Dates | start 2007-09-01, primary completion 2011-12-01, completion 2012-12-01, first posted 2007-09-14, last updated 2015-04-22 |
| Locations | 5 sites in Belgium, France, Netherlands, United Kingdom |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Acute Myocardial Infarction All trials of CD133+ infusion All trials of placebo infusion
An international, multi-centre, double-blind, randomised, placebo-controlled clinical trial with central core lab analyses to determine the safety of intra-coronary infusion of enriched CD133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute percutaneous coronary revascularization (primary PCI) for ST-segment elevation myocardial infarction (STEMI).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 1 | Active comparator | Other: CD133+ infusion | Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries |
| 2 | Placebo comparator | Other: placebo infusion | Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections. |
Sex: All, ages: 20 Years to 75 Years
Inclusion Criteria: * Primary PCI for acute STEMI between 2-24 hours after onset of chest pain. * ST-segment elevation >=2mm in >=3 adjacent leads. * Presence of severe hypokinesia and/or akinesia in >=2 adjacent segments on echocardiogram at 48-72 hrs after primary PCI. * Age between 20 and 75 years. Exclusion Criteria: * Pregnant or lactating. * Prior history of myocardial infarction before index event. * Decompensated congestive heart failure. * Pre-existent LV dysfunction (EF <45% prior to admission) * Cardiomyopathy. * Previous cardiac surgery. * Congenital heart disorder. * Serum creatinine >200 Mmol/L. * Presence of permanent pacemaker or implantable defibrillator. * Contraindication to bone marrow aspiration. * History of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma. * Sustained or inducible VT >48 hours post primary PCI. * Three vessel coronary artery disease necessitating intervention within 4 months. * Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. * Presence of chronic systemic inflammatory disorders. * Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation. * Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count. * Any condition associated with a life expectancy of less than 6 months. * Participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing. * Current alcohol or drug abuse. * Inability to provide written informed consent.
| Facility | City | Country | Status |
|---|---|---|---|
| OLVZ Aalst | Aalst | Belgium | |
| CHU ST-Pierre | Brussels | Belgium | |
| HĂ´pital Cardiologique | Lille | France | |
| Catharina Ziekenhuis | Eindhoven | Netherlands | |
| King's College University Hospital | London | United Kingdom |